



Vor to Participate in Two Upcoming Investor Conferences

January 4, 2022

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:

H.C. Wainwright BioConnect 2022 Virtual Conference

Presentation Date: Monday, January 10, 2022

Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET

2022 B Riley Virtual Oncology Conference

Fireside Chat Live Webcast Date: Thursday, January 27, 2022

Time: 10:30 AM ET

The live and on demand webcasts of both presentations will be available on the Company's website at www.vobrbio.com. An archived replay of each webcast will also be available.

About Vor Biopharma

Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contacts:

Investors:

Chris Brinzey

ICR Westwicke

+1 339-970-2843

chris.brinzey@westwicke.com

Media:

Sarah Spencer

Vice President, Corporate Communications, Vor

+1 857-242-6076

sspencer@vorbio.com